Evaluation of prasugrel compared with clopidogrel in patients with acute coronary syndromes: design and rationale for the TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet InhibitioN with prasugrel Thrombolysis In Myocardial Infarction 38 (TRITON-TIMI 38)
- 31 October 2006
- journal article
- research article
- Published by Elsevier BV in American Heart Journal
- Vol. 152 (4), 627-635
- https://doi.org/10.1016/j.ahj.2006.04.012
Abstract
No abstract availableThis publication has 25 references indexed in Scilit:
- Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery diseaseEuropean Heart Journal, 2006
- Pharmacology of CS-747 (prasugrel, LY640315), a Novel, Potent Antiplatelet Agent with in Vivo P2Y12Receptor Antagonist ActivitySeminars in Thrombosis and Hemostasis, 2005
- Randomized Trial of High Loading Dose of Clopidogrel for Reduction of Periprocedural Myocardial Infarction in Patients Undergoing Coronary InterventionCirculation, 2005
- Clopidogrel Loading With Eptifibatide to Arrest the Reactivity of PlateletsCirculation, 2005
- Variability in platelet responsiveness to clopidogrel among 544 individualsJournal of the American College of Cardiology, 2005
- Clopidogrel ResistanceCirculation, 2004
- Clopidogrel Resistance Is Associated With Increased Risk of Recurrent Atherothrombotic Events in Patients With Acute Myocardial InfarctionCirculation, 2004
- Clopidogrel for Coronary StentingCirculation, 2003
- The Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) trial programme. Rationale, design and baseline characteristics including a meta-analysis of the effects of thienopyridines in vascular diseaseEuropean Heart Journal, 2000
- The in vivo pharmacological profile of CS‐747, a novel antiplatelet agent with platelet ADP receptor antagonist propertiesBritish Journal of Pharmacology, 2000